AR096526A1 - Agentes citotóxicos para el tratamiento del cáncer - Google Patents
Agentes citotóxicos para el tratamiento del cáncerInfo
- Publication number
- AR096526A1 AR096526A1 ARP140102188A ARP140102188A AR096526A1 AR 096526 A1 AR096526 A1 AR 096526A1 AR P140102188 A ARP140102188 A AR P140102188A AR P140102188 A ARP140102188 A AR P140102188A AR 096526 A1 AR096526 A1 AR 096526A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- therapeutically effective
- composition according
- effective substance
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Método para tratar el cáncer cerebral que comprende administrar una sustancia terapéuticamente eficaz a un paciente, donde la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de la misma, donde X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH. Reivindicación 19: Una composición farmacéutica para utilizar en el tratamiento del cáncer cerebral caracterizada porque comprende a sustancia terapéuticamente eficaz, donde la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de la misma, donde X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH. Reivindicación 21: La composición farmacéutica de acuerdo con la reivindicación 20, caracterizada porque el agente citotóxico es una antraciclina. Reivindicación 22: La composición farmacéutica de acuerdo con la reivindicación 21, caracterizada porque la antraciclina se selecciona del un grupo formado por doxorubicina, daunorubicina, epirubicina, idarubicina, valrubicina, pirarubicina, zorubicina, aclarubicina, caminomicina, mitoxantrona y ametantrona, o un derivado de cualquiera de los mencionados o una sal farmacéuticamente aceptable de cualquiera de los mencionados. Reivindicación 24: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 23, caracterizada porque el grupo de unión covalente a la proteína se selecciona del grupo formado por maleimida, haloacetamida, haloacetato, piririltio, éster de N-hidroxisuccinimida, isotiocianato, disulfuro, vinilcarbonilo, aziridina y acetileno. Reivindicación 26: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 25, caracterizada porque el ligante comprende un residuo molecular orgánico que contiene, al menos, una cadena de carbono alifático que tiene 1 - 12 átomos de carbono, algunos de los cuales pueden reemplazarse con heteroátomos, o una porción aromática. Reivindicación 28: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 27, caracterizada porque el agente citotóxico y el ligante están unidos por una porción de hidrazona. Reivindicación 29: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 28, caracterizada porque la sustancia terapéuticamente eficaz tiene la estructura de fórmula (2). Reivindicación 35: La composición farmacéutica de acuerdo con la reivindicación 19, caracterizada porque la sustancia terapéuticamente eficaz se administra en combinación con un agente anti-cáncer. Reivindicación 55: Un kit que comprende a sustancia terapéuticamente eficaz para utilizar en el tratamiento del cáncer cerebral, caracterizado porque la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de la misma, caracterizado porque X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361831219P | 2013-06-05 | 2013-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR096526A1 true AR096526A1 (es) | 2016-01-13 |
Family
ID=52008558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140102188A AR096526A1 (es) | 2013-06-05 | 2014-06-05 | Agentes citotóxicos para el tratamiento del cáncer |
Country Status (12)
Country | Link |
---|---|
US (2) | US10278981B2 (es) |
EP (1) | EP3003489B1 (es) |
JP (1) | JP2016521705A (es) |
KR (3) | KR20210059035A (es) |
CN (2) | CN113842392A (es) |
AR (1) | AR096526A1 (es) |
AU (1) | AU2014274940B2 (es) |
BR (1) | BR112015030623A2 (es) |
CA (1) | CA2912908C (es) |
NZ (1) | NZ631022A (es) |
TW (1) | TW201446251A (es) |
WO (1) | WO2014197569A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2912908C (en) | 2013-06-05 | 2021-06-08 | Cytrx Corporation | Cytotoxic agents comprising covalently protein binding groups for treating brain cancer |
MX2018002293A (es) | 2015-08-25 | 2018-09-05 | Nantomics Llc | Sistemas y métodos para las llamadas variantes de alta precisión. |
KR20230115351A (ko) | 2017-08-15 | 2023-08-02 | 난트셀, 인크. | Hank 세툭시맙 조합 및 방법 |
CN108218932B (zh) * | 2017-12-27 | 2019-01-04 | 北京大学 | 凝集素受体介导的癌症预靶向治疗药物 |
WO2019142490A1 (ja) * | 2018-01-19 | 2019-07-25 | Delta-Fly Pharma株式会社 | がん患者の治療に有用な尿のアルカリ剤 |
US20190358201A1 (en) * | 2018-05-25 | 2019-11-28 | Nantcell, Inc. | Modified doxorubicin compositions and methods |
US12085571B2 (en) | 2019-06-13 | 2024-09-10 | Immunitybio, Inc. | Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
ATE357214T1 (de) | 1996-12-30 | 2007-04-15 | Battelle Memorial Institute | Verwendung eines unverkapselten anti-krebs- wirkstoffs zur herstellung einer zubereitung zur behandlung von neoplasmen durch inhalation |
DE19926154A1 (de) * | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
US20050148534A1 (en) | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
WO2005048822A2 (en) * | 2003-11-18 | 2005-06-02 | Attenuon Llc | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
EP2144504A4 (en) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | METHOD FOR COMBATING BRAIN CANCER |
KR20100029764A (ko) | 2007-05-16 | 2010-03-17 | 케이티비 투머포슝스케쉘샤프트 엠비에이치 | 저점성 안트라사이클린 제제 |
MX2011004019A (es) * | 2008-10-15 | 2011-06-24 | Angiochem Inc | Conjugados de etoposido y doxorubicina para entrega de farmacos. |
CN101897667B (zh) * | 2009-05-26 | 2012-01-25 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸多柔比星脂质体注射剂及其制备工艺 |
EP2382993A1 (en) * | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
DK2931042T3 (da) * | 2012-12-13 | 2021-06-07 | Cytrx Corp | Anthracyclinformuleringer |
CA2912908C (en) | 2013-06-05 | 2021-06-08 | Cytrx Corporation | Cytotoxic agents comprising covalently protein binding groups for treating brain cancer |
-
2014
- 2014-06-04 CA CA2912908A patent/CA2912908C/en active Active
- 2014-06-04 AU AU2014274940A patent/AU2014274940B2/en active Active
- 2014-06-04 CN CN202111190632.5A patent/CN113842392A/zh active Pending
- 2014-06-04 CN CN201480032023.9A patent/CN105307724A/zh active Pending
- 2014-06-04 WO PCT/US2014/040872 patent/WO2014197569A1/en active Application Filing
- 2014-06-04 US US14/893,821 patent/US10278981B2/en active Active
- 2014-06-04 KR KR1020217014703A patent/KR20210059035A/ko active Application Filing
- 2014-06-04 JP JP2016517955A patent/JP2016521705A/ja active Pending
- 2014-06-04 KR KR1020237015736A patent/KR20230070328A/ko not_active Application Discontinuation
- 2014-06-04 NZ NZ631022A patent/NZ631022A/en unknown
- 2014-06-04 BR BR112015030623A patent/BR112015030623A2/pt not_active IP Right Cessation
- 2014-06-04 KR KR1020157036829A patent/KR102257647B1/ko active IP Right Grant
- 2014-06-04 EP EP14807006.3A patent/EP3003489B1/en active Active
- 2014-06-05 AR ARP140102188A patent/AR096526A1/es unknown
- 2014-06-05 TW TW103119626A patent/TW201446251A/zh unknown
-
2019
- 2019-02-19 US US16/279,737 patent/US10881678B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016521705A (ja) | 2016-07-25 |
CA2912908A1 (en) | 2014-11-12 |
AU2014274940B2 (en) | 2019-05-23 |
EP3003489B1 (en) | 2021-08-18 |
US20160089388A1 (en) | 2016-03-31 |
BR112015030623A2 (pt) | 2017-07-25 |
CN105307724A (zh) | 2016-02-03 |
CN113842392A (zh) | 2021-12-28 |
EP3003489A1 (en) | 2016-04-13 |
EP3003489A4 (en) | 2017-02-08 |
US20190350952A1 (en) | 2019-11-21 |
TW201446251A (zh) | 2014-12-16 |
AU2014274940A1 (en) | 2015-12-03 |
US10278981B2 (en) | 2019-05-07 |
KR20160015289A (ko) | 2016-02-12 |
US10881678B2 (en) | 2021-01-05 |
CA2912908C (en) | 2021-06-08 |
WO2014197569A1 (en) | 2014-12-11 |
NZ631022A (en) | 2018-05-25 |
KR20230070328A (ko) | 2023-05-22 |
KR102257647B1 (ko) | 2021-05-31 |
KR20210059035A (ko) | 2021-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
ES2811367T3 (es) | Análogos de éteres fosfolipídicos como vehículos de fármacos que seleccionan como objetivo el cáncer | |
US10426841B2 (en) | Combination of drugs with protein-binding prodrugs | |
US9801949B2 (en) | Combinations of albumin-based drug delivery systems | |
NZ745069A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
BR112014015274A8 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
JPH04500209A (ja) | トポイソメラーゼ阻害剤または細胞分化誘導剤としての五環式トリテルペノイド化合物 | |
AR129578A1 (es) | MODULADORES DE LA ACTIVIDAD DE TNF-a | |
AR127245A1 (es) | Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos | |
BR112023026735A2 (pt) | Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica | |
BR112019000049A2 (pt) | terapias combinadas para o tratamento do câncer | |
AR128539A1 (es) | Terapias combinadas para el tratamiento de cánceres con moléculas de unión terapéuticas | |
AR013234A1 (es) | Derivados de amida y una composicion farmaceutica que los contiene |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |